华法林和阿司匹林联用在大鼠体内的药代动力学研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (2): 189-194.

华法林和阿司匹林联用在大鼠体内的药代动力学研究

黄晓晖¹, 王夏芹², 唐海沁², 王钦¹, 陈纭¹, 李谨², 李俊¹

¹安徽医科大学药学院,合肥 230032,安徽;
²安徽医科大学第一附属医院心内科,合肥 230022,安徽

收稿日期:2011-12-09 修回日期:2012-01-20 出版日期:2012-02-26 发布日期:2012-03-12

Pharmacokinetic interaction between warfarin and aspirin in rats

HUANG Xiao-hui¹, WANG Xia-qin², TANG Hai-qin², WANG Qin¹, CHEN Yun¹, LI Jing², LI Jun¹

¹Department of Basic and Clinical Pharmacology, ,School of Pharmacy, Anhui Medical University ,Hefei 230032, Anhui, China;
²Department of cardiology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui , China

Received:2011-12-09 Revised:2012-01-20 Online:2012-02-26 Published:2012-03-12
About author:HUANG Xiao-hui, associate professor of quantitative pharmacology and clinical pharmacokinetics.
Tel: 13855183138 E-mail: mathdrug@sina.com

摘要/Abstract

摘要： 目的: 探讨华法林和阿司匹林联用在大鼠体内非稳态和稳态条件下的药代动力学相互作用的规律,为临床合理药物联用提供依据。方法: 将大鼠随机分为3组,即华法林组(0.2 mg/kg),阿司匹林组(10 mg/kg),华法林(0.2 mg/kg)＋阿司匹林组(10 mg/kg)联用组,每组6只,给大鼠灌胃,连续 6 d,在第1天和第6天多个时间点取样,分析和比较非稳态和稳态下血药浓度时间曲线和药代动力学参数。结果: 华法林药动学用二室模型描述,阿司匹林药动学用一室模型描述。在非稳态和稳态下,阿司匹林单用和联用的血药浓度-时间曲线相似,药代动力学参数之间均无统计学差异;在非稳态下,华法林单用和联用的血药浓度-时间曲线也类似,但在稳态下,联用的血药浓度时间曲线明显高于单用时的曲线,药代动力学计算结果也表明联用时的AUC和C_max较单用时较大,且有统计意义。结论: 当华法林和阿司匹林联用达到稳态时,阿司匹林对华法林的药动学参数有影响,增大了华法林的暴露(AUC和C_max)。提示两药联用时,很可能增大患者的出血风险,临床上药物联用时应该注意。

关键词: 华法林, 阿司匹林, 药物联用, 药代动力学

Abstract: AIM: To explore the pharmacokinetic interaction between warfarin and aspirin in rats at non-steady-state and steady-state.METHODS: Three groups of six rats each were used according to a parallel study. Group I (warfarin) received daily repeated 0.2 mg/kg intragastric administration. Group II (aspirin) received daily repeated 10 mg/kg intragastric administration. Group III (warfarin plus aspirin) was administered as drug combination, namely daily oral dose of 0.2 mg/kg warfarin and 10 mg/kg aspirin. The rats received once daily repeated oral administration for 6 days. Plasma drug concentrations were obtained at scheduled time points on the first and the 6th day after dosing. The pharmacokinetic profiles and calculated parameters were analyzed and compared.RESULTS: The pharmacokinetics of warfarin and aspirin were best fitted to a two-compartment and one compartment model, respectively. At non-steady-state, the concentration-time course and related parameters of warfarin and aspirin was not changed by each other. At steady-state, the pharmacokinetic characteristics of warfarin were also not changed by aspirin. However, after multiple doses, Aspirin increased the peak plasma concentration and area under the curve of warfarin at steady-state.CONCLUSION: At steady-state after multiple dosing, aspirin increased the exposure of warfarin, which indicates that the combination therapy may increase the bleeding risk. This increase may represent a safety concern. The results suggest some differences of pharmacokinetic properties between warfarin and aspirin combinations at steady state, which indicates that when warfarin and aspirin are administered together, therapeutic drug monitoring should be enhanced.

Key words: Warfarin, Aspirin, Drug interaction, Pharmacokinetics

中图分类号:

R969

黄晓晖, 王夏芹, 唐海沁, 王钦, 陈纭, 李谨, 李俊. 华法林和阿司匹林联用在大鼠体内的药代动力学研究[J]. 中国临床药理学与治疗学, 2012, 17(2): 189-194.

HUANG Xiao-hui, WANG Xia-qin, TANG Hai-qin, WANG Qin, CHEN Yun, LI Jing, LI Jun. Pharmacokinetic interaction between warfarin and aspirin in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 189-194.

参考文献

[1] Fisher M. Dose the combination of warfarin and aspirin have a place in secondary stroke prevention NO[J] ? Stroke, 2009, 40(5):1944-1945.
[2] Furlan AJ. Dose the combination of warfarin and aspirin have a place in secondary stroke prevention YES[J] ? Stroke, 2009,40(5):1942-1943.
[3] Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction[J]. N Engl J Med, 2002, 347(13): 969-974.
[4] Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet -warfarin therapy after coronary stenting[J]. Eur Heart J, 2007,28(6):726-732.
[5] Lip GYH, Varma C. Anticagulation plus aspirin following acute myocardial infarction: Yes or No. if the latter. Why not[J] ? Thromb Res, 2006, 118(4):429-432.
[6] Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study[J]. Circulation, 2002, 105(5):557-563.
[7] Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increase severe bleeding events in patients with stroke and cardiovascular disease: a prospective multicenter, observational study[J]. Stroke, 2008,39(6): 1740-1745.
[8] Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy[J]. Sroke, 2005, 36(7): 1588-1593.
[9] Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy alone and amone patients at risk for cardiovascular disease[J]. Arch Int Med, 2007, 167(2): 117-124.
[10] Madhwal S, Lincoff AM, Rolston DD. Should patients on long-term warfarin take aspirin for heart disease[J] ? Cleve Clin J Med, 2008,75(3):206-208.
[11] Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of comining aspirin with anticoagulation therapy in patients with atrial fibrillation; an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTF) trials[J]. Am Heart J, 2006, 152(5): 967-973.
[12] Suda K, Kudo Y, Higaki T, et al.Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease[J].Circ J, 2009,73(7):1319-1323.
[13] Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure[J]. Circulation, 2009,119(12):1616-1624.
[14] Donnan GA, Davis SM. Combined aspirin plus warfarin: recent evidence and residual questions[J]. Stroke, 2009, 40(5):1946.
[15] Fiske WD, Connell JM, Benedek IH. Lack of pharmacokinetic interaction between aspirin and warfarin[J]. Am J Ther, 1995,2(6):407-413.
[16] Shircman TI, Howard PA, Kresonik TF, et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients[J]. Stroke,2004, 35(10):2212-2267.
[17] Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulation therapy in patients with atrial fibrillation: an exploratory anslysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTF) trials[J]. Am Heart J, 2006, 152(5):967-973.
[18] Mohapatra R, Tran M, Gore JM, et al. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era[J]. Am Heart J, 2005, 150(1):19-26.
[19] Gorelick PB. Combing aspirin with oral anticoagulant therapy: Is this a safe and effective practice in patients with atrial fibrillation[J] ? Stroke, 2007,38(5): 1652-1654.